Loading...
OTCM
EPGNF
Market cap702kUSD
Jul 01, Last price  
1.12USD
Name

Epigenomics AG

Chart & performance

D1W1MN
OTCM:EPGNF chart
P/E
—
P/S
37.12
EPS
—
Vol. 1Y
—
Shs. 5Y
24.38%
Rev. 5Y
-50.92%
Div Yld LY
—
Div Yld TTM
—
Revenues
24k
3,566,9262,567,0002,586,0004,260,0001,787,0001,437,0001,039,0001,588,0001,507,0002,082,0004,201,0001,864,0001,533,0001,125,000842,0006,203,000485,000339,227023,990
Net income
-314k
L-90.63%
-15,402,000-13,151,000-12,271,000-10,223,000-11,476,000-15,575,000-12,197,000-7,411,000-8,854,000-8,985,000-11,161,000-10,235,000-12,692,000-17,020,000-11,686,000-2,428,000-12,024,000-4,463,523-3,351,034-313,882
CFO
-6m
L-52.50%
-9,242,9637,501,000-14,636,209-11,516,000-9,800,000-10,629,000-9,479,000-9,111,000-10,884,000-6,505,000-7,221,000-8,127,000-13,283,000-9,576,000-10,351,000-13,506,000-9,571,000-4,152,000-12,024,000-5,711,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA and, HCCBloodTest, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma. The company was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo G. Gut in 1998 and is headquartered in Berlin, Germany.

Key people

Hansjoerg Plaggemars
Member of the Management Board · since 2024
Alexander Link
Deputy Chairman of the Supervisory Board · since 2021
Helge Lubenow
Chairwoman of the Supervisory Board · since 2023
Jochen Hummel
Member of the Supervisory Board · since 2024
URL
https://www.epigenomics.com/
IPO date
Jul 19, 2004
Employees
36
Domiciled in
DE
Incorporated in
DE
Headquarters & legal address
Ziegelhäuser Landstraße 3
Heidelberg, BW 69120
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT